Biogen (BIIB) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We are substantially dependent on revenue from our products
2. 02Our long-term success depends upon the successful development of new products and additional indications for our existing products
3. 03If we fail to compete effectively, our business and market position would suffer
4. 04Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives
5. 05While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth
6. 06Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations
7. 07Our results of operations may be adversely affected by current and potential future healthcare reforms
8. 08Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected

Risks Related to Intellectual Property

1. 09If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed

Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates

1. 10Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product
2. 11Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied
3. 12Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price

Risks Related to Our Operations

1. 13A breakdown or breach of our information systems could subject us to liability or interrupt the operation of our business
2. 14The increasing use of AI-based software presents new risks and challenges and could adversely affect our business and reputation
3. 15Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue
4. 16Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products
5. 17In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations
6. 18If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business
7. 19may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support
8. 20Additionally, conditions and regulations governing the health care industry in the U.S. are subject to greater risk of change and uncertainty as a result of changes in legislative and regulatory priorities and personnel
9. 21Our sales and operations are subject to the risks of doing business internationally
10. 22Although the Solothurn facility was approved by the FDA for LEQEMBI, there can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of other products
11. 23The illegal distribution and sale by third-parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business
12. 24The increasing use of social media platforms presents new risks and challenges

Risks Related to Holding Our Common Stock

1. 25Our operating results are subject to significant fluctuations
2. 26Our investments in properties may not be fully realized
3. 27We may not be able to access the capital and credit markets on favorable terms, which could increase our financing costs
4. 28Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business
5. 29Our investment portfolio is subject to market, interest and credit risk that may reduce its value
6. 30There can be no assurance that we will repurchase shares or that we will repurchase shares at favorable prices, which may negatively affect our stock price
7. 31Some of our collaboration agreements contain change in control provisions that may discourage a third-party from attempting to acquire us
8. 32Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts in our financial statements
9. 33Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements
10. 34Our business involves environmental and operational risks, which include the cost of compliance and the risk of contamination or injury